ClinicalTrials.gg
Status unknownNCT05244460DOPEUpdated Jan 20, 2023

Droperidol on Prevention of Cannabis Hyperemesis Syndrome

A Phase 3 interventional study of Droperidol Injectable Product and Diphenhydramine in Cannabis Hyperemesis Syndrome, sponsored by Mercy Health Ohio. Status unknown at 4 sites in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-01-20.

Sponsored by Mercy Health Ohio · Phase 3, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Jan 2023), so the status shown — last known as Recruiting — may be out of date.
Phase
Phase 3
Study type
Interventional
Enrollment
45
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to assess the efficacy of droperidol as a treatment of cannabinoid hyperemesis syndrome.

Read the detailed description

Patients presenting to the Emergency Department with nausea, vomiting and/or abdominal pain with a significant history of cannabis use and symptoms in a cyclic pattern will be assessed for study inclusion. After given written informed consent, patients will be treated with droperidol and diphenhydramine and symptoms will be assessed using a visual analog scale at time intervals up to 120 minutes. Patient will then be contacted at 24 and 48 hour intervals to assess symptoms on the same scale. This is a multicenter, prospective interventional study with results compared to a historical cohort using haloperidol.

02

Conditions studied

  • Cannabis Hyperemesis Syndrome
03

In context

Lead sponsor

Mercy Health Ohio is the lead sponsor of 15 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • aged 18 years of age or older and presenting with cannabis hyperemesis syndrome requiring intravenous medication.

Exclusion criteria

Exclusion Criteria:

  • any patient with a to the use of droperidol
  • interval on greater than 440 milliseconds for males and greater than 450 milliseconds for females
  • any prisoners
  • pregnant females.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
45 participants (estimated)

Study arms

  • Experimental
    Intervention

    Patients who receive droperidol 2.5mg intravenous once and diphenhydramine 25mg intravenous once

    Drug: Droperidol Injectable Product · Drug: Diphenhydramine

Interventions

06

What researchers measure

Primary outcomes

  1. Change from baseline in symptoms after treatment with droperidol and diphenhydramine

    The Visual Analog Scale is a 100-mm patient-reported score measurement used to assess nausea and/or vomiting and/or abdominal pain. Possible scores range from 0 (symptom-free) to 10 (worst possible symptom)

    Time frame: Baseline, 30 minutes, 60 minutes and 120 minutes. Then at 24 hours and 48 hours.

07

Study locations

4 of 4 sites recruiting
  • Mercy Health - Austintown
    Austintown, Ohio 44515, United States
    Recruiting
  • St Elizabeth Boardman Hospital
    Boardman, Ohio 44512, United States
    Recruiting
  • St. Joseph-Warren Hospital
    Warren, Ohio 44484, United States
    Recruiting
  • St Elizabeth Youngstown Hospital
    Youngstown, Ohio 44501, United States
    Recruiting
08

References and documents

Publications

  • Ruberto AJ, Sivilotti MLA, Forrester S, Hall AK, Crawford FM, Day AG. Intravenous Haloperidol Versus Ondansetron for Cannabis Hyperemesis Syndrome (HaVOC): A Randomized, Controlled Trial. Ann Emerg Med. 2021 Jun;77(6):613-619. doi: 10.1016/j.annemergmed.2020.08.021. Epub 2020 Nov 5. PubMed 33160719 ↗
  • Lee C, Greene SL, Wong A. The utility of droperidol in the treatment of cannabinoid hyperemesis syndrome. Clin Toxicol (Phila). 2019 Sep;57(9):773-777. doi: 10.1080/15563650.2018.1564324. Epub 2019 Feb 7. PubMed 30729854 ↗
  • Hickey JL, Witsil JC, Mycyk MB. Haloperidol for treatment of cannabinoid hyperemesis syndrome. Am J Emerg Med. 2013 Jun;31(6):1003.e5-6. doi: 10.1016/j.ajem.2013.02.021. Epub 2013 Apr 10. PubMed 23583118 ↗

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 20, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05244460
Lead sponsor
Mercy Health Ohio
Collaborators
Lake Erie College of Osteopathic Medicine
Responsible party
Sponsor
First posted
Feb 17, 2022
Start date
Dec 2, 2021
Primary completion
Jan 31, 2023 (estimated)
Completion
Jan 31, 2023 (estimated)
Last update
Jan 20, 2023

Study contacts

Todd Bolotin, MD
Contact
tbolotin@mercy.com
3302193838
Quincy Chopra, MD
Contact
qchopra@mercy.com
4128059742
Todd Bolotin, MD
principal investigator · Mercy Health

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Droperidol

Start the discussion